STAT+: House panel advances bill to extend Medicare’s telehealth flexibilities, setting up December talks
A House committee on Wednesday advanced legislation that would extend Medicare telehealth flexibilities and a…
Category: STAT+
STAT+: In race to make gene therapy for age-related blindness, 4D Molecular announces positive results
A long-running race to develop a gene therapy for the most common cause of age-related…
STAT+: Hospital giant Ascension recorded about $1.3 billion in losses from its cyberattack
The cyberattack that forced Ascension to shut off access to its electronic health records cost…
STAT+: Pharmalittle: We’re reading about pharma patent maneuvers, the U.S. warning J&J, and more
Hello, everyone, and how are you today? We are muddling along, but the middle of…
STAT+: Roivant strikes another deal, selling dermatology spinoff to Organon in deal worth $1.2 billion
Roivant Sciences continues its dealmaking hot streak, announcing Wednesday that it would sell one of…
STAT+: Drugmakers rely on ‘use codes’ to vastly expand the nature of their patent claims, STAT analysis shows
Amid debate over potential abuse of the U.S. patent system by the pharmaceutical industry, moves…
STAT+: U.S. agency threatens J&J with sanctions if it switches payments to 340B hospitals
A U.S. government agency has threatened Johnson & Johnson with sanctions if the company proceeds…
STAT+: From Epic to FDA, all the leaders presenting at HHS’ invite-only AI in health care event
Federal health officials wrestling with when and how to use artificial intelligence will on Wednesday…
STAT+: Democrats keep IVF in the spotlight with another Senate vote
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: Pharmalittle: We’re reading about an Express Scripts lawsuit against FTC, AMR deaths, and more
Top of the morning to you, and a fine one it is, despite the gray…
STAT+: 11 people shaping psychedelics drug development
The field of psychedelics, once relegated to the fringes of science and medicine, is in…
STAT+: What pharma companies and insurers think about Medicare’s plan to cover digital treatments
In July, Medicare proposed to start paying for some mental health apps, in a move…
A documentary film asks: Can health systems improve patient safety by embracing new tech?
Reetam Ganguli once pitched his technology, to rescue women from pregnancy complications, in an airplane…
STAT+: Most cardiovascular devices with serious safety recalls aren’t tested in patients
When someone’s heart doesn’t beat quite right, an implantable defibrillator can save their life. The…
STAT+: What Medicare Advantage enrollment could look like for next year
You’re reading the web version of Health Care Inc., STAT’s weekly newsletter following the flow…
STAT+: After 10 years of game-changing immunotherapies, a cancer conference celebrates — and sees more work to do
BARCELONA, Spain — Ten years ago, a new type of cancer treatment reached the market….
STAT+: Top staffer on drug pricing to depart Senate Finance Committee
WASHINGTON – Shawn Bishop, the Democratic staffer who drafted much of the drug pricing portion…
STAT+: Pharmalittle: We’re reading about an AstraZeneca bladder cancer drug, Genentech anxiety, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Genentech, a biotech with a storied past, confronts new turbulence in the present
For decades, the biotech company Genentech has carved out a reputation in the industry as…
STAT+: Exact Sciences reports initial positive results in colon cancer blood test, but pivot trial still pending
Exact Sciences, which has for years sold a stool-based colon cancer test, on Monday announced…
STAT+: AstraZeneca’s Imfinzi increases survival rates in bladder cancer in pivotal study
BARCELONA, Spain — An AstraZeneca immunotherapy, given both before and after surgery, improved survival rates…
STAT+: Checkpoint inhibitor staves off disease progression in anal cancer trial
BARCELONA, Spain — A widely used immunotherapy approach helped stave off disease progression in patients…
STAT+: Pfizer drug shows promise in cancer-related condition that causes weight loss and weakness
BARCELONA, Spain — Patients with advanced cancers often develop a secondary condition that causes them…
STAT+: BMS immunotherapy boosts responses in lung cancer, setting up Phase 3 study
BARCELONA, Spain — Adding a second immunotherapy from Bristol Myers Squibb to an existing checkpoint…
STAT+: Lung cancer drug from iTeos, GSK shows response, boosting TIGIT as a viable target
BARCELONA, Spain — A targeted immunotherapy being developed by the biotech iTeos Therapeutics and GSK…
STAT+: FDA approves Roche’s injectable version of blockbuster multiple sclerosis drug
Swiss pharma giant Roche won approval from the Food and Drug Administration on Friday for…
STAT+: ‘I’m still here’: Before Alzheimer’s, he prided himself on his intellect
Truck. Banana. Violin. Desk. Green. Sitting behind her desk in an examining room, the neurologist…
STAT+: Pharmalittle: We’re reading about Bavarian Nordic’s mpox shot, a crackdown on Ozempic prescribing and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Why these health tech leaders are making a risky bet, openly backing Trump or Harris
Silicon Valley startup founders and venture capital investors are picking a side in this year’s…
STAT+: Insurers went all-in on Medicare Advantage. Now, some are scaling back
For years, health insurers battled to gain market share in the lucrative privatized Medicare program….
Opinion: STAT+: What does the presidential election mean for ICHRA and the health insurance market?
Over the past two presidential administrations, the health care market has changed dramatically with the…
STAT+: A new drug offers a rare option for brain cancer treatment — and inspires hopes for more
For more cancer coverage, sign up for STAT’s pop-up newsletter focused on this weekend’s European…
STAT+: How efforts to cancel medical debt could wind up benefitting hospitals
You’re reading the web edition of D.C. Diagnosis, STAT’s twice-weekly newsletter about the politics and…
STAT+: ‘Put him in jail.’ Steward CEO de la Torre skips hearing, now Congress is poised to hold him in contempt
Lawmakers in Washington turned their focus to the Steward Health Care bankruptcy scandal on Thursday,…
STAT+: Can iTeos and GSK solve TIGIT’s troubles?
This is the online edition of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can…
STAT+: Pharmalittle: We’re reading about Moderna R&D cuts, Lilly plant investments and more
Rise and shine, everyone, another busy day is on the way. However, this is also…
STAT+: Gilead’s twice-yearly antiviral protects against HIV infection in second large trial
Gilead said Thursday that its twice-yearly antiviral reduced the risk of HIV infections by 96%…
STAT+: Moderna touts research progress as it cuts R&D spending by $1.1 billion
Moderna said Thursday it would cut its annual spending on research and development by 23%,…
STAT+: Apple will offer millions of AirPod users a hearing aid. Can it convince them to use it?
After years of dabbling in hearing health, Apple earlier this week went all-in, announcing that…
Opinion: STAT+: How to keep the BIOSECURE Act from hobbling U.S. biotech and pharma
In a rare display of bipartisan agreement, Congress is getting serious about addressing China’s influence…
STAT+: A rare disease program, portrayed as both lifeline and pharma handout, is set to expire
After his son Michael was diagnosed with a devastating, ultra-rare disease in 2019, Terry Pirovolakis…
STAT+: Key Senate Republican throws cold water on Affordable Care Act repeal, site-neutral payment policy
WASHINGTON — A key Senate Republican dismissed the idea that the Affordable Care Act can…
STAT+: FDA commissioner: Health systems have to ‘step up’ on AI regulation or will ‘end up holding the bag’
WELLESLEY, Mass. — Amid heated discussions on how artificial intelligence should be regulated and who…
STAT+: FDA scolds AbbVie over ‘misleading’ TV ad for a migraine pill featuring Serena Williams
The U.S. Food and Drug Administration has scolded AbbVie for making false and misleading claims…
STAT+: ‘Sarepta’s like a curse on me’: FDA commissioner dismisses controversy over approval
WELLESLEY, Mass. — At an event with journalists Tuesday outside of Boston, U.S. Food and…
STAT+: How hospitals could make money off of Kamala Harris’ medical debt relief plan
WASHINGTON — The largest health system in North Carolina simply wasn’t interested in canceling its…
STAT+: Q&A: For this South Dakota health system, leaning into telehealth means learning ‘webside’ manner
Fighting a massive snowstorm to get to the doctor in the Dakotas is an unpleasant…
STAT+: After FDA rejection, Sanofi and Regeneron’s Dupixent succeeds in late-stage trial of chronic hives
Sanofi and Regeneron’s blockbuster drug Dupixent successfully treated patients with chronic spontaneous urticaria, an inflammatory…
STAT+: Elevance buys IU Health’s insurance company
Elevance Health, the parent of more than a dozen state Blue Cross Blue Shield plans,…
STAT+: Novo Nordisk’s amylin pill leads to substantial weight loss in early study
Novo Nordisk on Tuesday reported that its new obesity pill that targets the amylin hormone…